Search Results - "REUTER, V"

Refine Results
  1. 1

    Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma by IWAMOTO, F. M, ABREY, L. E, BEAL, K, GUTIN, P. H, ROSENBLUM, M. K, REUTER, V. E, DEANGELIS, L. M, LASSMAN, A. B

    Published in Neurology (13-10-2009)
    “…Bevacizumab has recently been approved by the US Food and Drug Administration for recurrent glioblastoma (GBM). However, patterns of relapse, prognosis, and…”
    Get full text
    Journal Article
  2. 2
  3. 3

    Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer by Attard, G, Clark, J, Ambroisine, L, Fisher, G, Kovacs, G, Flohr, P, Berney, D, Foster, C S, Fletcher, A, Gerald, W L, Moller, H, Reuter, V, De Bono, J S, Scardino, P, Cuzick, J, Cooper, C S

    Published in Oncogene (10-01-2008)
    “…New predictive markers for managing prostate cancer are urgently required because of the highly variable natural history of this disease. At the time of…”
    Get full text
    Journal Article
  4. 4

    The Pathology of Renal Epithelial Neoplasms by Reuter, Victor E.

    Published in Seminars in oncology (01-10-2006)
    “…Renal epithelial neoplasms are morphologically diverse and are characterized by distinct genetic abnormalities. In addition, our understanding of these…”
    Get full text
    Journal Article
  5. 5

    Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer by Reid, A H M, Attard, G, Ambroisine, L, Fisher, G, Kovacs, G, Brewer, D, Clark, J, Flohr, P, Edwards, S, Berney, D M, Foster, C S, Fletcher, A, Gerald, W L, Møller, H, Reuter, V E, Scardino, P T, Cuzick, J, de Bono, J S, Cooper, C S

    Published in British journal of cancer (16-02-2010)
    “…Background: The discovery of ERG/ETV 1 gene rearrangements and PTEN gene loss warrants investigation in a mechanism-based prognostic classification of prostate…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement by Foster, C S, Dodson, A R, Ambroisine, L, Fisher, G, Møller, H, Clark, J, Attard, G, De-Bono, J, Scardino, P, Reuter, V E, Cooper, C S, Berney, D M, Cuzick, J

    Published in British journal of cancer (06-10-2009)
    “…Background: This study was performed to test the hypothesis that expression of small heat shock protein Hsp-27 is, at diagnosis, a reliable predictive…”
    Get full text
    Journal Article
  8. 8

    ADAM12 is highly expressed in carcinoma-associated stroma and is required for mouse prostate tumor progression by PEDUTO, L, REUTER, V. E, SEHARA-FUJISAWA, A, SHAFFER, D. R, SCHER, H. I, BLOBEL, C. P

    Published in Oncogene (31-08-2006)
    “…The interaction between stromal cells and tumor cells is emerging as a critical aspect of tumor progression. Yet there is a paucity of molecular markers for…”
    Get full text
    Journal Article
  9. 9

    Mobile dementia counseling as low-threshold assistance for caregiving relatives by Reichert, Monika, Hampel, S, Reuter, V

    “…Comprehensive and easily accessible information and counseling for people with dementia and their caregivers can improve home care in many ways; however, for…”
    Get full text
    Journal Article
  10. 10
  11. 11

    Surgical management of renal tumors 4 cm. or less in a contemporary cohort by Lee, C T, Katz, J, Shi, W, Thaler, H T, Reuter, V E, Russo, P

    Published in The Journal of urology (01-03-2000)
    “…We evaluated a patient cohort with renal tumors 4 cm. or less treated with partial or radical nephrectomy. We compared patient and tumor characteristics, and…”
    Get more information
    Journal Article
  12. 12

    Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study by Berney, D M, Gopalan, A, Kudahetti, S, Fisher, G, Ambroisine, L, Foster, C S, Reuter, V, Eastham, J, Moller, H, Kattan, M W, Gerald, W, Cooper, C, Scardino, P, Cuzick, J

    Published in British journal of cancer (24-03-2009)
    “…Treatment decisions after diagnosis of clinically localised prostate cancer are difficult due to variability in tumour behaviour. We therefore examined one of…”
    Get full text
    Journal Article
  13. 13

    Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature by CHANG, S. S, REUTER, V. E, HESTON, W. D. W, BANDER, N. H, GRAUER, L. S, GAUDIN, P. B

    Published in Cancer research (Chicago, Ill.) (01-07-1999)
    “…Prostate-specific membrane antigen (PSMA) is a type II integral membrane glycoprotein that was initially characterized by the monoclonal antibody (mAb) 7E11…”
    Get full text
    Journal Article
  14. 14

    Long-term outcome among men with conservatively treated localised prostate cancer by CUZICK, J, FISHER, G, SCARDINO, P, KATTAN, M. W, BERNEY, D, OLIVER, T, FOSTER, C. S, MØLLER, H, REUTER, V, FEARN, P, EASTHAM, J

    Published in British journal of cancer (06-11-2006)
    “…Optimal management of clinically localised prostate cancer presents unique challenges, because of its highly variable and often indolent natural history. There…”
    Get full text
    Journal Article
  15. 15

    Cystectomy for bladder cancer: a contemporary series by Dalbagni, G, Genega, E, Hashibe, M, Zhang, Z F, Russo, P, Herr, H, Reuter, V

    Published in The Journal of urology (01-04-2001)
    “…To validate the current TNM staging system, we analyzed our contemporary experience with 300 cystectomies. The pathological material and medical records of 300…”
    Get more information
    Journal Article
  16. 16

    Prostate-specific Membrane Antigen Is Produced in Tumor-associated Neovasculature by CHANG, S. S, O'KEEFE, D. S, BACICH, D. J, REUTER, V. E, HESTON, W. D. W, GAUDIN, P. B

    Published in Clinical cancer research (01-10-1999)
    “…Prostate-specific membrane antigen (PSMA), a type II transmembrane protein, was originally thought to be strictly expressed in prostatic tissue, but recent…”
    Get full text
    Journal Article
  17. 17

    Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer by Zelefsky, M J, Leibel, S A, Gaudin, P B, Kutcher, G J, Fleshner, N E, Venkatramen, E S, Reuter, V E, Fair, W R, Ling, C C, Fuks, Z

    “…Three-dimensional conformal radiation therapy (3D-CRT) is a technique designed to deliver prescribed radiation doses to localized tumors with high precision,…”
    Get more information
    Journal Article
  18. 18
  19. 19

    Primary renal synovial sarcoma: Molecular and morphologic delineation of an entity previously included among embryonal sarcomas of the kidney by ARGANI, P, FARIA, P. A, EPSTEIN, J. I, REUTER, V. E, PERLMAN, E. J, BECKWITH, J. B, LADANYI, M

    Published in The American journal of surgical pathology (01-08-2000)
    “…We report 15 primary renal neoplasms with morphologic, immunohistochemical, and molecular features identical to those of synovial sarcoma. These tumors form a…”
    Get full text
    Journal Article
  20. 20

    Contemporary approach to the classification of renal epithelial tumors by Reuter, V E, Presti, Jr, J C

    Published in Seminars in oncology (01-04-2000)
    “…Our understanding of the morphologic and genetic features of renal epithelial neoplasia has brought about profound changes in the classification of these…”
    Get more information
    Journal Article